{
  "docId": "019de075-12bd-74a7-bc75-4587e4948a57",
  "docSlug": "9c54f748d4238e6a3a690a4101a45e99",
  "documentTitle": "Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 41,
  "pageCount": 50,
  "prevPage": 40,
  "nextPage": 42,
  "slideType": "key_messages",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a bispecific antibody illustration to represent the combination therapy approach.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-12bd-74a7-bc75-4587e4948a57/41",
  "deckHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57",
  "deckJsonHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57.json",
  "deckAnchorHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57#slide-41",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.35,
        "y": 0.23
      },
      "kind": "callout",
      "text": "Established combination precedent: JNJ VEGA study demonstrated unprecedented efficacy despite sub-optimal combination components",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f5c2970-3aa1-44bc-b224-d081d0a63505",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.5,
        "y": 0.46
      },
      "kind": "callout",
      "text": "Rapid proof of concept: Parallel progression of portfolio of mAbs will allow evaluation of combinations in Phase 2 studies",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "82c4cd82-6863-41b5-b6ff-d26eb64f48a8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.66,
        "y": 0.23
      },
      "kind": "callout",
      "text": "Ideal building blocks: Spyre's best-in-class engineered mAbs provide optionality for multiple rational combinations",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c9103d2c-4ecb-4515-ba57-d3e78215cb0a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.55,
        "x": 0.4,
        "y": 0.7
      },
      "kind": "diagram",
      "text": "UPCOMING CATALYSTS: 2025 Ph2 initiation with SPY001 backbone",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca545100-1c15-4f1d-98bb-f1a94b3c47b8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.02,
        "y": 0.25
      },
      "kind": "image",
      "text": "Bispecific antibody illustration",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b86becbe-bce9-4278-a6a4-9bf2d13026d3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.1,
        "x": 0.12,
        "y": 0.7
      },
      "kind": "list",
      "text": "SPY130, SPY120, SPY230",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "73434ec1-7c1f-443c-8a3f-112fb54a5545",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Spyre is developing potentially best-in-class combinations to maximize efficacy for patients with IBD",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b9e6207e-8f0b-4150-9066-406fc7885277",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "AIDA Model",
      "slug": "aida-model",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "e4216b9a-ef1c-4817-a81d-39071fef1ee5",
      "evidence": "callout/primary: Rapid proof of concept: Parallel progression of portfolio of mAbs will allow evaluation of combinations in Phase 2 studies",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "9a3de97d-512a-445d-b70d-d827423a2e8e",
      "evidence": "The bottom section displays a chronological progression of upcoming catalysts.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}